ASH 2022 | Vulnerabilities in lipid synthesis pathways and resistance to IMiDs and CELMoDs in multiple myeloma
Sarah Bird, MD, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, discusses findings from a laboratory study which generated multiple myeloma models with acquired immunomodulatory drugs (IMiDs)/cereblon E3 ligase modulators (CELMoDs) resistance. Multiomics analysis, including DNA sequencing and CRISPR screening, was performed and it was found that there were common changes in the lipid synthesis pathway across all models. With this novel knowledge, Dr Bird hopes that agents which target the lipid synthesis pathway may provide a new therapeutic option for patients with multiple myeloma with IMiDs/ CELMoDs resistance. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
